We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Praxair (PX) Hikes Gas Prices to Fund Investment Needs
Read MoreHide Full Article
Industrial gas producer and supplier Praxair Inc. (PX - Free Report) recently hiked the prices of industrial and medical gases for its bulk gas customers in the U.S. and its territories. The revised prices will be effective from Jul 15, 2016.
As revealed, prices of nitrogen, oxygen, argon, hydrogen, helium and carbon dioxide have been increased up to 15%.
Praxair cited the need to fund capital investments for improving in its production and distribution capabilities as the reason behind the rise in prices. Earlier, the company had increased its industrial and medical gas prices in Dec 2015 to support rising costs and higher investment needs.
We believe Praxair’s profitability is highly dependent on costs of sales and expenses, as any unwarranted increase in these will lower the profitability and vice versa. However, increasing application has been raising the demand for industrial gases over time, proving beneficial for companies like Praxair. Exiting first-quarter 2016, the company had a solid backlog of $1.5 billion. In addition, Praxair boasts a diversified product portfolio and a large worldwide client base. Over the last 60 days, the Zacks Consensus Estimate for Praxair has remained stable at $1.35 per share for second-quarter 2016 and $5.56 for 2016, while the same has inched down 0.2% to $6.15 for 2017.
Despite the long-term positives, the company’s exposure to certain near-term headwinds has restricted its growth momentum. Currently, the stock has a market capitalization of $32.4 billion and carries a Zacks Rank #3 (Hold).
Some of Praxair’s prime competitors are performing well, having gained high investment rankings. These stocks include Albemarle Corporation (ALB - Free Report) , Axiall Corporation and Innophos Holdings Inc , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Praxair (PX) Hikes Gas Prices to Fund Investment Needs
Industrial gas producer and supplier Praxair Inc. (PX - Free Report) recently hiked the prices of industrial and medical gases for its bulk gas customers in the U.S. and its territories. The revised prices will be effective from Jul 15, 2016.
As revealed, prices of nitrogen, oxygen, argon, hydrogen, helium and carbon dioxide have been increased up to 15%.
Praxair cited the need to fund capital investments for improving in its production and distribution capabilities as the reason behind the rise in prices. Earlier, the company had increased its industrial and medical gas prices in Dec 2015 to support rising costs and higher investment needs.
We believe Praxair’s profitability is highly dependent on costs of sales and expenses, as any unwarranted increase in these will lower the profitability and vice versa. However, increasing application has been raising the demand for industrial gases over time, proving beneficial for companies like Praxair. Exiting first-quarter 2016, the company had a solid backlog of $1.5 billion. In addition, Praxair boasts a diversified product portfolio and a large worldwide client base. Over the last 60 days, the Zacks Consensus Estimate for Praxair has remained stable at $1.35 per share for second-quarter 2016 and $5.56 for 2016, while the same has inched down 0.2% to $6.15 for 2017.
PRAXAIR INC Price and Consensus
PRAXAIR INC Price and Consensus | PRAXAIR INC Quote
Despite the long-term positives, the company’s exposure to certain near-term headwinds has restricted its growth momentum. Currently, the stock has a market capitalization of $32.4 billion and carries a Zacks Rank #3 (Hold).
Some of Praxair’s prime competitors are performing well, having gained high investment rankings. These stocks include Albemarle Corporation (ALB - Free Report) , Axiall Corporation and Innophos Holdings Inc , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>